肺癌治疗新突破!康方生物依沃西单抗全球III期临床数据更新

药事纵横
Sep 09, 2025

9月7日,在WCLC会议上,康方生物的海外合作伙伴Summit Therapeutics公布了依沃西单抗(AK112)首个全球III期临床研究HARMONi的更新数据。数据显示,随着随访时间延长,依沃西在总生存期(OS)方面的获益进一步显现。意向治疗人群(ITT)的OS风险比(HR)降至0.78,p=0.0332;尤其北美人群的生存获益更加显著,HR达到0.70。图源:康方生物官媒依沃西单抗是康方...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10